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Abstract Urethral stricture disease is increasingly common occurring in about 1% of males
over the age of 55. The stricture tissue is rich in myofibroblasts and multi-nucleated giant cells
which are thought to be related to stricture formation and collagen synthesis. An increase in
collagen is associated with the loss of the normal vasculature of the normal urethra. The actual
incidence differs based on worldwide populations, geography, and income. The stricture aeti-
ology, location, length and patient’s age and comorbidity are important in deciding the course
of treatment. In this review we aim to summarise the existing knowledge of the aetiology of
urethral strictures, review current treatment regimens, and present the challenges of using
tissue-engineered buccal mucosa (TEBM) to repair scarring of the urethra. In asking this ques-
tion we are also mindful that recurrent fibrosis occurs in other tissuesdhow can we learn from
these other pathologies?
ª 2018 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
Urethral strictures are an abnormal narrowing of the ure-
thra. The origins of this fibrosis may be due to intrinsic
conditions but commonly occur in response to damage or
infection [1]. They represent a scarring of the vascular
corpus spongiosum leading to fibrosis [2]. There are varying
degrees of spongiofibrosis but obstruction of the urethra
can cause infection, bladder calculi, fistulas, sepsis, and
renal failure.
Overall the incidence of urethral strictures is about 1% in
the males over the age of 55. The actual incidence differs
basedonworldwidepopulations,geography,andincome[1,3].
Management of strictures varies from less invasive
techniques such as urethral dilatation and urethrotomy, to
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more invasive procedures such as anastomotic and substi-
tution urethroplasty [4]. In patients who have extensive
disease, obtaining sufficient graft can be challenging. For
this reason, tissue-engineered buccal mucosa (TEBM) for
the treatment of complex strictures was developed [5,6].
2. Urethral stricture and histopathology
The normal urethra is lined by pseudo stratified columnar
epithelium anchored to a basement membrane beneath
which there is connective tissue composed of fibroblasts in
an extracellular matrix composed of collagen, pro-
teoglycans, elastic fibres and glycoproteins. Under this is
the spongiosum composed of vascular sinusoids and smooth
muscle. The pathological changes associated with strictures
show that the normal epithelium becomes replaced with
squamous metaplasia [7]. All strictures involve some injury
to the epithelium of the urethra or corpus spongiosum and
fibrosis occurs during the subsequent healing process.
This stricture tissue is rich in myofibroblasts and multi-
nucleated giant cells which are thought to be related to
stricture formation and collagen synthesis, respectively. An
increase in collagen is associated with the loss of the normal
vasculature of the normal urethra. Singh and Blandy [8]
reported an experimental study in the rat to determine
the role of extravasation of urine in the pathogenesis of
urethral stricture. They observed that the ultrastructure of
urethral stricture tissue suggested that some strictures were
fibrous while others were more resilient, and the total
amount of collagen increased in urethral strictures, result-
ing in dense fibrotic tissue with decreased smooth muscle
tissue and decreased elasticity. In contrast, Baskin et al. [9]
could not demonstrate an increase in the total amount of
collagen in strictures compared with the normal urethra,
but rather found that an alteration in the ratio of collagen
type may explain the fibrotic, non-compliant nature of
urethral stricture scar tissue. They found that the normal
urethral spongiosum was composed of 75% type I collagen
and 25% type III collagen. In contrast, the type III collagen in
urethral stricture tissue was increased to 84% with a corre-
sponding decrease in type I collagen (to 16%). These changes
were accompanied by a decrease in the ratio of smooth
muscle to collagen, as well as changes in the synthesis of
nitric oxide in the urethral stricture tissue [10]. Glycos-
aminoglycans (GAGs) and collagens are major components
of the extracellular matrix and they have key roles in
fibrotic diseases. Da-Silva et al. [11] measured the GAG
composition in the strictured urethral segment. They
concluded that composition changes in GAGs could
contribute to the non-compliant nature of urethral scar
tissue and cause functional changes. Anterior urethral
strictures normally occur after trauma or inflammation, and
result in spongiofibrosis. Posterior urethral strictures
generally result from iatrogenic injury or occur after pelvic
fractures. These injures are contractures or stenosis of the
urethra rather than true strictures.
2.1. Aetiology of urethral strictures
Urethral stricture disease can occur due to several different
aetiologies (Table 1) [12]. Strictures can be due to
iatrogenic, idiopathic, inflammatory or traumatic causes.
The largest category is actually iatrogenic resulting from
urethral manipulations, related to placing of indwelling
catheters, transurethral manipulation, surgery for hypo-
spadias, prostatectomy, and brachytherapy [13,14] (Fig. 1).
Strictures can also occur due to trauma associated with
pelvic fractures and in approximately 60% of patients the
function of the distal sphincter mechanism and hence
continence depends on the integrity of the bladder neck.
Moving on to infection, untreated gonorrhoea and chla-
mydia causing urethritis can lead to strictures. Another
inflammatory disease associated with urethral stricture is
balanitis xerotica obliterans. This is a chronic inflammatory
disease whose aetiology is still unknown [15].
3. Clinical evaluation
The first important step in the evaluation of a patient and
the decision about treatment is to obtain a thorough history
to get as much information as possible about the aetiology
behind the urethral stricture. This requires documenting the
onset and severity of obstructive and storage-related void-
ing symptoms. In addition to this history, uroflowmetry is
widely used in the assessment of the urethral stricture.
Retrograde urethrography is used to provide information on
stricture location and length. Moreover, retrograde and
antegrade cystourethrographies are recommended to assess
posterior urethral strictures and bladder neck function [16].
Cystoscopy can show the location and degree of the stric-
ture, but if the stricture cannot be passed, no information
can be obtained. Another diagnostic procedure is ultraso-
nography which can be helpful in the assessment of the
stricture length and the degree of spongiofibrosis [17].
Table 1 Stricture aetiology by location [12].
Penile, % Bulbar, %
Iatrogenic 40 35
Idiopathic 15 40
Inflammatory 40 10
Traumatic 5 15
Figure 1 Iatrogenic stricture aetiology (%) by location [13].
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4. Management
Treatment of urethral strictures depends on stricture
aetiology, localisation (anterior or posterior), the length of
stricture, the degree of spongiofibrosis, the previous history
of treatment, and the patient’s age. Theoretically, short
simple strictures are treated endoscopically, however long
complex strictures often require one- or two-stage ure-
throplasty (Fig. 2).
4.1. Urethral dilation and internal urethrotomy
There are several methods for urethral dilatation. These
encompass sequential dilatation with metal sounds though
filiform dilations, followers, dilation with a balloon, and
self-dilation with catheters. The success of these all de-
pends on the regeneration of epithelium without it leading
to further restenosis. For patients with an epithelial stric-
ture without spongiofibrosis, dilatation can be curative and
overall there is no difference in recurrence rates following
internal urethrotomy versus urethral dilation [18,19].
Internal urethrotomy [19] is performed by a cold-knife
transurethral incision to release stricture tissue. The goal
is to provide a minimally invasive treatment that achieves a
patent urethra to allow unobstructed voiding with minimal
side effects. For the urethra to remain patent, reepitheli-
alization must occur at a faster rate than wound
contracture [20]. For patients who are carefully selected
with optimal stricture characteristics, primary bulbar
strictures of <1 cm which are soft, then a stricture-free
rate of up to 50%e70% can be achieved. Thus, ure-
throtomy remains the first-line therapy for these selected
patients [21,22]. Steenkamp et al. [19] reported long-term
success rates of only 20%. Patients with longer (>2 cm in
length), multiple, penile or distal strictures and extensive
periurethral spongiofibrosis typically do not respond well to
repeat incisions. Thus repeat internal urethrotomy offers
no real chance of a cure after a third incision or if the
stricture recurs within 3 months of the first incision. Such
patients should be offered urethroplasty [23,24].
Some studies have evaluated the efficacy of agents
injected into the scar tissue at the site of stricture area as
an internal urethrotomy procedure to decrease recurrence
rates. For example mitomycin C was used for anterior
urethral stricture and bladder neck contractions. Authors
found that after 15 months mean follow-up urethral stric-
ture recurred in 10% urethral stricture patients in the
mitomycin C treated group and in 50% of patients in the
untreated group [25,26]. Another study evaluated the use
of triamcinolone injection and showed a significant
decrease in recurrence rate [27,28]. Incision/dilation fol-
lowed by long-term self- or office dilation is an alternative
option for men with severe comorbidities or limited life
expectancy, or for those who have failed prior reconstruc-
tion with no further available surgical options.
Figure 2 Algorithm of anterior urethral stricture treatment (A) and bulbar urethral stricture treatment (B) [4].
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Internal urethrotomy can have complications such as
urethral hemorrhage, perineal hemorrhage and extravasa-
tion of irrigation into perispongiosal tissues, scrotal
oedema, creation of a false passage, rectal perforation,
epididymo-orchitis, meatal stenosis, incontinence, fever,
bacteremia, urinary sepsis, and scrotal abscess. With deep
incisions at the 10 o’clock and 2 o’clock positions, there is
also a risk of entering the corpus cavernous and creating
fistulas between corpus spongiosum and cavernous, leading
to erectile dysfunction [28e31]. Overall, however, the
incidence of these complications is around 2%e10% but in
addition there can be recurrence of the urethral strictures.
While the procedure can be done with cold-knife there
have been studies [32e34] looking at the use of lasers for
the treatment of urethral strictures. Many different types
of lasers have been used including argon, carbon dioxide,
excimer, diode, KTP and Nd:YAG lasers. Unfortunately the
bottom line is that the addition of lasers has not improved
success rates compared to cold-knife urethrotomy.
5. Urethroplasty
5.1. Excision and primary anastomosis
The lowest re-stricture rate with least complications is
achieved by excising the stricture, particularly where this is
a short bulbar urethral stricture of <2 cm in length and
achieving an anastomosis of the two healthy ends on either
side [2,35]. Success rates are reported to be between 90%
and 95% [36e39].
The length that can be gained depends on the anatomy
of the individual patient, as well as the length and elasticity
of the distal urethral segment, and more particularly, the
size of the penis and urethra. By separating the corpora or
freeing the urethra from the corpus cavernous up to the
peno-scrotal junction as much as 2e4 cm in length can be
gained. Additionally, younger men may have better tissue
compliance, increasing the chances of successful primary
re-anastomosis for long strictures [38].
This excision and primary anastomosis appears to have a
negligible effect on penile shortening or chordae if more
than 2 cm of urethra is excised. Another important
complication is sexual dysfunction. Erickson et al. [40]
found that when patients did report postoperative erec-
tile dysfunction after urethral reconstruction, it tended to
be transient, with the vast majority of patients recovering
preoperative erectile function within 6 months of surgery.
Erectile function may be influenced by patient age, stric-
ture length and location, and the method of reconstruction.
5.2. Augmentation urethroplasty
Augmentationurethroplasty is traditionally used for strictures
longer than 2 cm for which an anastomotic urethroplasty
is not suitable for surgery. These techniques are recom-
mended to achieve a tension free anastomosis and to avoid
chordae. Augmentation urethral reconstruction can be a
one-stage or a two-stage procedure.
There are three potential options with a one-stage
procedure:
1) An augmented anastomotic procedure; Stricture excision
and then restore a roof or floor strip of native urethra
augmented with a patch.
2) An onlay augmentation procedure. This is incision of
stricture with an onlay patch to the urethral roof or floor
strip.
3) A tube augmentation: Excise the stricture and put in a
circumferential patch. This procedure is associated with
high recurrence rates [41,42].
A two-stage procedure involves excision of the stricture
and the abnormal urethra and reconstruction of a roof
strip, which is allowed to heal prior to second-stage
tubularisation.
Another approach to urethroplasty is the use of a graft or
flap. This was viewed as controversial but it is now clear
from a review of the literature that the stricture recurrence
rate is 14.5%e15.7% using either a flap or graft [43]. Thus
there is no advantage in the use of a flap over a straight-
forward graft in terms of stricture recurrence. In carrying
out an augmentation procedure, one must also consider
whether full-thickness tissue or partial-thickness tissue
should be used; Partial-thickness tissue has a greater pro-
pensity to contract than does full-thickness tissue. This is
exactly the same as what is found with graft contraction in
split-thickness skin where thinner skin grafts contract to a
much greater extent than do thicker skin grafts [44].
A range of materials have been used for grafting including
penile skin, scrotal skin, oral mucosa, bladder mucosa, and
colonic mucosa. From these oral mucosa grafts have become
the most clinically accepted due to their graft short harvest
time, a lack of hair, low morbidity, and their high clinical
success rates [45e48]. Oral mucosa is taken as full-thickness
and most patients can provide an adequate donor area. Oral
mucosa can be harvested from the cheek (buccal mucosa),
from the lip (labial mucosa), or from the undersurface of the
tongue (lingual mucosa). Labial mucosa can be managed in a
similar fashion, but is much thinner and more difficult to
handle, and has become associated with greater morbidity.
Reported complications of oral mucosal grafts include
intraoperative hemorrhage, postoperative infection, pain,
swelling, and damage to salivary ducts. In some cases, pa-
tients note initial limitation of oral opening, although this is
usually transient. Occasionally there can be loss or alteration
of sensation within the cheek. Barbagli et al. [49] reported
that 98.4% would undergo the surgery again and concluded
that harvesting from a single cheek with closure of the donor
site was a safe procedure with high patient satisfaction.
There are several different approaches to the augmen-
tation procedure. For onlay augmentation, the option is a
ventral, lateral, or dorsal approach. Dorsal and ventral
onlay grafts have comparable success rates of 88% at 3
years [50]. There is likely to be less bleeding from an
incision in this plane and potentially less interference with
blood supply as one extends into the proximal and distal
normal urethra. Barbagli et al. [51] described lateral onlay
augmentation and success rate remained at 83% over the
follow-up period.
Two-stage reconstruction should be considered after
hypospadias repair or in the presence of lichen sclerosus
(LS) or when there are other concerns about the success of
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any reconstructive procedure in the penile urethra. Several
months elapse while the first-stage reconstruction heals
and only when it is adequate for closure is the urethra
retubularised. After first-stage urethral reconstruction
10%e39% of patients show contraction because of scarring
initial graft unfortunately [52]. For example, nearly 15% of
men treated for urethral strictures have a history of failed
hypospadias repair [53]. Treatment of adults with recurrent
strictures is difficult because of the poor blood supply,
urethral shortening from prior surgery, the degree of
inflammation and the scarring itself.
In complex strictures due to previously failed hypospa-
dias or LS, these may require second-stage urethroplasty
with buccal mucosa. Commonly these patients require large
areas of buccal mucosa grafting.
5.3. Graft contraction or failure
While contraction of grafted tissue post urethral surgery is
a relatively common postoperative complication which
usually requires further surgery, this is not a unique situa-
tion. Skin grafts, for example, commonly contract.
The mechanism of skin or oral mucosa contraction is a
normal physiological phenomena which reduces the area of
the graft. The graft contraction occurs in two-stages. When
the graft is first harvested from the donor side, it undergoes
an initial reduction in size called primary contraction. This
can range from 9% to 22% dependent on the thickness of the
graft [54]. The thicker the skin grafts are, the more elastin
fibres will be present in the dermis and the greater these
contract. Thus full-thickness grafts exhibit the greatest
degree of primary contraction and split-thickness grafts
with less elastin fibres contract less and pure epidermal
grafts fail to contract [54]. When grafts are placed on their
recipient wound beds then they undergo secondary
contraction. This is the contraction that is of clinical
concern. This contraction reduces both the size of the graft
and the circumference of the graft at its periphery, with
the edges of the graft contracted towards the centre [55].
For secondary graft contraction, split-thickness grafts
contract more than full-thickness grafts [56]. It is thought
that this is due to the difference in matrix composition
between the dermal layers within the grafts [57].
Epidermal hyperplasia and dermal fibrosis are less promi-
nent in full-thickness grafts than split-thickness grafts at
4 weeks after grafting [57].
Certainly it is known that the graft bed and the recip-
ient exert a major influence on the degree of contraction.
Grafting onto more mobile tissues results in more
contraction. Also age plays a big role. Grafts in paediatric
patients contract more frequently and to a greater extent
than in adults. This may be related to the growth factor
profile of children compared to adults [47,58,59]. Looking
at the cellular mechanisms of contraction there is
considerable evidence that contraction occurs secondary
to the differentiation of fibroblasts to form myofibroblasts
with expression of alpha-actin filament bundles. These
myofibroblasts possess intrinsic contractile properties
similar to smooth muscle cells. As the myofibroblasts are
adherent both to one another and to the fibronectin-rich
wound bed, the entire mass of granulation tissue
contract [60e62]. Keratinocytes are also capable of con-
tracting collagen gels in vitro and their role is increasingly
recognised in vivo [63]. Keratinocytes possess strong
intercellular adhesions, with cultured confluent sheets of
keratinocytes rapidly contracting to 70% of their original
area following detachment from tissue culture plastic
in vitro [64]. Keratinocytes are also effective at con-
tracting collagen gels when they are seeded on the top of
the gel. This mimics the in vivo situation, in which the
keratinocytes migrate across the wound surface during
reepithelialisation. At relatively low densities of surface-
seeded keratinocytes, the contraction is equivalent to
that seen with much higher densities of gel-incorporated
human dermal fibroblasts [65].
Our group has developed a 3D tissue engineered model of
human skin, based on sterilised human dermis. This is
seeded with laboratory-expanded human keratinocytes and
fibroblasts and cultured at an aireliquid interface [66,67].
This tissue-engineered skin is based on normal mature
human cross-linked collagen. It retains a basement mem-
brane [68], to which keratinocytes attach firmly and form a
stratified epithelium, while fibroblasts penetrate and
migrate through the dermis. This tissue engineered skin
contracts by 25%e40% during 10 days of culture in vitro
[69,70] and by up to 60% over 30 days of culture [67]. It
appears that keratinocytes contract the dermis as they
differentiate. Increasing keratinocyte differentiation with
Vitamin C provokes premature differentiation and hyper-
keratosis with a marked increase in keratinocyte-driven
contraction of the tissue-engineered skin [70]. This change
appears to be mediated by covalent crosslinking of adjacent
collagen fibrils. Culture of tissue-engineered skin with b-
aminopropionitrile (b-APN), an inhibitor of the lysyl oxidase
crosslinking enzyme, leads to a reduction in contraction
in vitro [67]. These findings have also been seen in a
fibroblast-impregnated collagen gel model where lysyl
oxidase-catalysed collagen crosslinking is observed during
the contraction process and again this contraction can be
inhibited by b-APN [71]. Interestingly this keratinocyte-
mediated contraction can be reduced in vitro by suturing
the tissue engineered skins to a rigid frame for a number of
days [72]. It is known that skin graft contracture is more
severe in children than in adults, although the reason for
this is not clear. There are changes in transforming
growth factor-b (TGF-b) expression with age and a reduction
in expression of TGF-b1 and TGF-b2 expression with
ageing, accompanied by an increase in TGF-b3 [41]. Up-
regulations of TGF-b1 and TGF-b2 have been proposed as
a primary mechanism for hypertrophic and keloid scarring
[73]. Insulin-like growth factor-1 (IGF-1) plays a major role
in wound healing [74]. Synthesis of IGF-1 leads to increased
collagen synthesis and deposition [75]. It shares many
fibrogenic characteristics with TGF-b1 and is found in
elevated levels in hypertrophic scar tissue when compared
with patient matched normal skin [76]. Using a tissue
engineered model of skin in vitro, IGF-1 was found to have
no significant effect on contraction [67]. Similarly addition
of exogenous basic fibroblast growth factor (bFGF), tumour
necrosis factor-a (TNFa) and prostaglandin-E2 (PGE2) had no
effect on contraction [67]. Interestingly, culture with
estradiol resulted in a marked increase in contraction,
although the reason for this is unclear.
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In 2008 there was a randomized comparative study of 30
patients who were treated either with native buccal mu-
cosa or an acellular bladder matrix graft. It was found that
the results were related to the number of previous in-
terventions. In patients who had less than two prior oper-
ations, the success rate of the bladder matrix graft was
eight out of nine cases but for those who had more than two
operations, four out of the six patients were unsuccessful.
This study showed that the best results were obtained in
patients with a healthy urethral bed, no spongiofibrosis and
good urethral mucosa [77].
In 2008 we reported the first use of tissue-engineered
buccal mucosa for extensive substitution urethroplasty in
five patients and here we reported on a 3-year follow-up.
We found that initial results were good in all five patients
with rapid vascularisation of the grafts and retubularisa-
tion of all five patients occurred as though native buccal
mucosa had been used. However, after 8 and 9 months
respectively, two of the five patients’ grafts developed
contraction and fibrosis. One graft was completely
removed and one was partially removed and replaced by
native buccal mucosa. Histology of the two excised grafts
showed pronounced epithelial hyperproliferation and
fibrosis [5].
A recent 9-year follow-up in 2014 showed no further
fibrosis for the four patients who had tissue engineered
buccal mucosa still in place. In this study all the patients
had same aetiology with significant LS [6].
In 2011 there was a report of the use of tissue engi-
neered autologous urethrografts for patients who needed
reconstruction. Another cell-seeded scaffolds were used in
a series of five pediatric patients with posterior urethral
stricture, a tissue biopsy was taken from each patient, and
the muscle and epithelial cells were seeded onto tubu-
larised polyglycolic acid:poly (lactide-co-glycolide acid)
scaffolds. Patients then underwent urethroplasy with tissue
engineered scaffolds. Median follow-up was 71 months and
successful in 4/5 patients, and 1/5 patients required tran-
surethral incision 4 weeks after surgery. The patient was
able to void well without further interventions [72]. In 2012
a report was published of six pediatric patients with severe
hypospadias who were treated with urothelial cells seeded
onto an acellular dermis graft. Follow-up was for a median
of 7.25 years. Five out of the six patients had a good
cosmetic appearance and outcome. In one patient an in-
ternal urethrotomy was performed 1 year after ure-
throplasy [78].
After these mixed clinical results we decided we needed
to undertake further investigation of the mechanism of
contraction of TEBM in vitro before going forward clinically.
Our first study of contraction of TEBM showed that they
lost a mean of 45.4% of their original surface area over 28
days of culture. Treating TEBM with glutaraldehyde, b-APN,
or mechanical restraint during culture all significantly
inhibited graft contraction. Glutaraldehyde treatment
was most effective during culture reduction graft contrac-
tion [79].
Several studies reported long-term success rates of
urethroplasty with patient’s buccal mucosa graft
[41e43,45e51]. A few studies published multivariate
analysis of urethroplasy out-comes examining preopera-
tive parameters predictors of recurrence (Table 2).
Breyer et al. [80] reported their cohort of 445 patients
undergoing urethroplasy with mean 5.8 years follow-up
period. They determined an overall recurrence rate of
21%. A history of smoking and prior urethral surgery (in-
ternal urethrotomy or urethroplasty) were found to be
significant predictors for recurrence. The authors also
noted that most of the recurrence occurred within the
first 2 years. Another study found the average time to
recurrence was 11.7 months, with recurrence occurring
between 2 weeks and 77 months and these authors also
noted that recurrences generally occurred early within
the first 6 months [81]. Multivariate analysis showed that
long stricture length (>5 cm), LS, iatrogenic and infection
were all associated with recurrence [81]. Warner et al.
[82] maintained that second-stage urethroplasties had a
higher recurrence rate compared with first-stage ure-
throplasty for LS cases. More recently, Han et al. [83]
examined their cohort of urethroplasty patients and
showed results of their multivariate analysis and found
prior urethroplasty was a predictor of follow-up but crit-
ically more strictures were detected on longer term
follow-up after urethroplasty. Authors found a mean time
to recurrence of 34 months, with recurrences occurring as
late at 87 months. On multivariate analysis, if follow-up
exceeded 48 months there was a statistically significant
increase in recurrence being detected. These results
confirm that late recurrences do occur even beyond 5
years of follow-up.
Fibrosis is an important pathology which can occur in
many other tissuesdliver cirrhosis, atherosclerosis,
Dupuytren’s contracture, and glomerulosclerosis. For
these diseases, early pathogenesis of fibrosis is related to
inflammation and the final pathways of fibrogenesis are
Table 2 Risk factors for stricture recurrence [80e83].
Factors Risk ratio (range)
Diseases
Smoking 1.8 (1.0e3.1)
Diabetes mellitus 2.0 (0.8e4.9)
Chronic obstructive pulmonary disease 1.3 (0.4e4.4)
Connective tissue disease 1.3 (0.3e4.7)
Coronary artery disease 1.0 (0.4e2.5)
Stricture aetiology
Trauma 2.6 (0.98e6.9)
Iatrogenic 3.4 (1.2e10)
Infectious 7.3 (2.3e23.7)
Lichen sclerosus 5.9 (2.1e16.5)
Radiation 3.3 (0.8e14)
Location
Anterior 0.49 (0.2e1.2)
Posterior 0.67 (0.3e1.7)
Panurethral 1.4 (0.38e5)
Prior treatment
Urethroplast 6.9 (2.1e22.6)
Urethrotomy 0.8 (0.2e2.8)
Dilation 0.7 (0.3e1.4)
Hypospadias 1.6 (0.7e3.9)
Stricture length >5 cm 2.3 (1.2e4.5)
Age 0.99 (0.98e1.01)
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similar and stereotypical. Alcoholic liver cirrhosis is a
fibrotic disease developing after toxic damage. In this
pathology, circulating autoantibodies against acetalde-
hyde adducts and lipid peroxidation-derived antigens are
detected [84]. T cells infiltrating the liver paranchyma are
also the first sign of increased extracellular matrix (ECM),
particularly type III collagen. As long as type III collagen
exists, fibrosis is still reversible, but the appearance of
type I collagen heralds an irreversible stage [85,86].
Atherosclerosis is characterized by sclerosis of the arterial
wall due to pathogenic fibrotic changes [87]. Like other
fibrotic disorders, an imbalance between profibrotic and
antifibrotic cytokines induces fibroblast proliferation and
hyper production of ECM [88]. Dupuytren’s contracture is
characterized by fibrotic nodules with progressive,
contraction of the palmar fascia. The aetiology of this
condition is still unclear. Pathological responses to trau-
matic stress factors may affect the microvasculature,
leading to localized ischemia and the generation of
oxygen-free radicals providing an inflammatory reaction in
this disease. This inflammatory response is followed by
the production of profibrotic TGF-b1. For this condition,
fibroblast transdifferentiation into myofibroblasts are
essential cellular components [89]. Another fibrotic pa-
thology is glomerulosclerosis. Here neutrophils are the
first cells recruited to glomerula. Neutrophil degranula-
tion, releasing inflammatory and profibrotic cytokines and
macrophages are the chief source of TGF-b1, finally
resulting in the end-stage of glomerular fibrosis [90]. Un-
fortunately despite this knowledge of the molecular and
cellular mechanisms of fibrosis in other conditions fibrosis
remains very difficult to treat. This research has not yet
translated into clinically applicable diagnostic, preven-
tive, and therapeutic measures.
In summary, urethral strictures are common and man-
agement of long segment strictures presents a challenging
surgical problem primarily because of stricture recur-
rence. There are clear predictors of which patients will be
most affecteddthose with comorbidities of diabetes
mellitus or coronary artery disease, smoking, stricture
aetiology (iatrogenic, infectious or LS), long strictures
stricture length, and prior urethroplasty. The use of TEBM
offers an additional treatment material but it is not
exempt from stricture recurrence. However what it does
provide is an in vitro model in which to explore ap-
proaches to prevent or reduce tissue contraction. Our
recent work looking at inhibitors of collagen crosslinking
may offer an approach to reducing its severity once
detected but this is an area where much more research is
needed to couple the clinical information on which pa-
tients are most at risk to early detection and eventually
treatment. Currently we conclude that it is an area of
unmet clinical need where users of tissue engineered
materials will need to be cautious and reported on long-
term clinical results.
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